MOMA-989

MOMA-989 is a small molecule (oral) from MOMA Therapeutics. An oral, highly potent, brain-penetrant selective PARP1 inhibitor, planned for homologous recombination deficient tumours alone and with MOMA-313. Its furthest stage is preclinical development, for homologous recombination deficient tumours. No clinical trial naming it is registered on ClinicalTrials.gov. In-licensed January 2025 from an unnamed US biopharmaceutical partner; MOMA then anticipated an IND by end of 2025. No ClinicalTrials.gov study names MOMA-989 (query.intr search, 3 Nov 2026), so it is kept at preclinical. It has not been shown to work in people.